Hepatitis C

Case of Psoriasis Remission After Hepatitis C Treatment

Case of Psoriasis Remission After Hepatitis C Treatment

A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.

Hepatitis C Drug Effective Against Zika Virus in Preclinical Trial

Hepatitis C Drug Effective Against Zika Virus in Preclinical Trial

By

The hepatitis C treatment, sofosbuvir was found to be effective against Zika virus in a preclinical trial.

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Provider-Pharmacy Collaboration Reduces DAA Initiation Delays in HCV

Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

Statewide Increase in Hepatitis C Virus Vertical Transmission Found

By

State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.

Treatment Regimens and Recommendations for HIV/HCV Coinfection

Treatment Regimens and Recommendations for HIV/HCV Coinfection

By

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

High Rates of SVR With Interferon-Free DAA for HCV GT1, Advanced Fibrosis

By

Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

By

Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

By

Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.

High Rates of SVR With DAAs in HCV/HIV Coninfection

High Rates of SVR With DAAs in HCV/HIV Coninfection

By

The advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection.

HBV, HCV Increases All-Cause, Liver-Related Mortality in HIV

HBV, HCV Increases All-Cause, Liver-Related Mortality in HIV

By

Hepatitis B and hepatitis C may increase mortality risks in patients with HIV.

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

Efficacy of LDV/SOF for Retreatment of Chronic HCV in SOF-Experienced Patients

By

The highest SVR12 rates were obtained with 12 weeks of LDV/SOF+RBV in noncirrhotic participants and by extending the duration of LDV/SOF treatment to 24 weeks in cirrhotic individuals.

Liver Damage Worse in Women With HBV/HCV Coinfection, Risky Drinking

Liver Damage Worse in Women With HBV/HCV Coinfection, Risky Drinking

By

The combined presence of alcohol abuse, HBV, and HCV generates an additive effect on the risk of cirrhosis in women than in men.

The Changing Face of HCV: Role of the Opioid Epidemic

The Changing Face of HCV: Role of the Opioid Epidemic

By

The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.

Association Between HBV, HCV and Age-Related Cataracts

Association Between HBV, HCV and Age-Related Cataracts

By

High aspartate aminotransferase levels completely mediated the effects of HBV infection on any cataract.

Drinking Coffee Reduces Mortality in HIV/HCV Coinfection

Drinking Coffee Reduces Mortality in HIV/HCV Coinfection

Drinking 3 or more cups of coffee per day halves all-cause mortality risk in patients co-infected with HIV/hepatitis C virus.

Racial Disparities in HCV Incidence and Treatment Outcomes

Racial Disparities in HCV Incidence and Treatment Outcomes

By

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

FDA Approves Labeling Update for Several HCV Drugs

FDA Approves Labeling Update for Several HCV Drugs

By

Updated labeling has been provided for several treatments for hepatitis C virus infections.

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

Effectiveness of Ledipasvir/Sofosbuvir for Acute HCV Infection in HIV

By

Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.

Preventing HCV Transmission: Utility of Needle/Syringe Programs

Preventing HCV Transmission: Utility of Needle/Syringe Programs

By

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject drugs in Europe and North America, respectively.

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

Reduced Risk of Hepatic Steatosis in HIV/HCV Coinfection With Cannabis Use

By

Daily cannabis use remained significantly associated with lower odds of steatosis even after adjustment for BMI, which is known to be inversely correlated with cannabis use.

Increasing HCV Screening Using Electronic Health Record Prompts

Increasing HCV Screening Using Electronic Health Record Prompts

By

The rates of anti-HCV orders and tests were collected from 4 medical specialties within a 30 mile radius of University of Michigan, Ann Arbor campus.

A New Treatment Option for Patients With HCV and Severe Renal Impairment

A New Treatment Option for Patients With HCV and Severe Renal Impairment

By

Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, exhibit potent antiviral activity across all six major HCV genotypes.

Hepatitis C Transmission With Increased Risk Donor Organs Examined

Hepatitis C Transmission With Increased Risk Donor Organs Examined

By

Given the ongoing shortage of liver grafts, transplantation from HCV increased-risk donors to anti-HCV-negative recipients could potentially expand the donor pool.

Using VA Models of Care for Reducing HCV Burden

Using VA Models of Care for Reducing HCV Burden

The US VA has developed models of care that can be used to reduce the overall burden of HCV infection.

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

Short-Duration Treatment Regimens for Chronic HCV: Latest Insights

By

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved treatment adherence, and a reduced rate of side effects.

HIV/HCV Coinfections: Barriers to Effective Treatment

HIV/HCV Coinfections: Barriers to Effective Treatment

By

Only a small percentage of people with HIV/HCV coinfection receive treatment for hepatitis C.

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

By

Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

By

The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

By

Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.

Development Program for Hepatitis C Treatments Discontinued

Development Program for Hepatitis C Treatments Discontinued

By

Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.

Sign Up for Free e-newsletters